Nuvalent (NUVL)

Executive Summary

Nuvalent is a precision oncology company developing novel, brain-penetrant small molecule kinase inhibitors designed to overcome resistance and improve outcomes in ROS1-, ALK-, and HER2-driven cancers. Its pipeline includes three lead candidates: zidesamtinib (NVL-520) for ROS1-positive NSCLC, neladalkib (NVL-655) for ALK-positive NSCLC, and NVL-330 for HER2-altered solid tumors. All are designed with structure-based approaches to achieve high selectivity, intracranial activity, and activity against a broad range of resistance mutations. The company is advancing these programs through Phase 1/2 and Phase 3 trials, with a focus on addressing high unmet needs in central nervous system metastases and acquired resistance to earlier-generation therapies. Nuvalent's most advanced program, neladalkib, is currently being evaluated in a Phase 3 trial in combination with alectinib for first-line ALK-positive NSCLC, with data expected to read out over the next few years. The company also expects to present updated clinical data from its Phase 1/2 trials for all three candidates at upcoming medical meetings. With a strong balance sheet and a clear focus on precision medicine, Nuvalent is well-positioned to become a leader in next-generation kinase inhibitors. The company's ability to demonstrate durable responses and a favorable safety profile will be key to its success.

Upcoming Catalysts (preview)

• Q2 2026Presentation of updated Phase 1/2 data for zidesamtinib (NVL-520) in ROS1-positive NSCLC at ASCO 202690% success
• Q3 2026Initiation of Phase 3 trial for NVL-330 in HER2-altered solid tumors70% success
• H2 2027Interim analysis from Phase 3 ALK-positive NSCLC trial of neladalkib + alectinib60% success